Fluoxetine protects against methamphetamine‑induced lung inflammation by suppressing oxidative stress through the SERT/p38 MAPK/Nrf2 pathway in rats

Wang,Yun; Gu,Yu‑Han; Liu,Ming; Bai,Yang; Wang,Huai‑Liang

doi:10.3892/mmr.2016.6072

Fluoxetine protects against methamphetamine‑induced lung inflammation by suppressing oxidative stress through the SERT/p38 MAPK/Nrf2 pathway in rats

Authors:
- Yun Wang
- Yu‑Han Gu
- Ming Liu
- Yang Bai
- Huai‑Liang Wang
View Affiliations

Affiliations: Department of Clinical Pharmacology, School of Pharmacy, China Medical University, Shenyang, Liaoning 110122, P.R. China, Department of Drug Control, China Criminal Police University, Shenyang, Liaoning 110035, P.R. China
Published online on: December 23, 2016 https://doi.org/10.3892/mmr.2016.6072
Pages: 673-680
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Methamphetamine (MA) abuse is a major public health and safety concern throughout the world and a growing burden on healthcare costs. The purpose of the present study was to investigate the protective effect of fluoxetine against MA‑induced chronic pulmonary inflammation and to evaluate the potential role of nuclear factor erythroid 2-related factor 2 (Nrf2)-mediated antioxidative stress. Wistar rats were divided into control, MA and two fluoxetine‑treated groups. Rats in the MA and the two fluoxetine‑treated groups were treated daily with intraperitoneal injection of 10 mg/kg MA twice daily. Rats in the two fluoxetine‑treated groups were injected intragastrically with fluoxetine (2 and 10 mg/kg) once daily, respectively. After 5 weeks, the rats were euthanized and hematoxylin and eosin staining, immunohistochemistry, western blot analysis and redox assay were performed. It was demonstrated that chronic exposure to MA can induce pulmonary inflammation in rats, with the symptoms of inflammatory cell infiltration, crowded lung parenchyma, thickened septum and a reduced number of alveolar sacs. Fluoxetine attenuated pulmonary inflammation and the expression of interleukin‑6 and tumor necrosis factor‑α in rat lungs. Fluoxetine inhibited MA‑induced increases in the expression levels of serotonin transporter (SERT) and p‑p38 mitogen‑activated protein kinase (MAPK), and reversed the MA‑induced decrease in nuclear Nrf2 and human heme oxygenase‑1 in lungs. Fluoxetine at 10 mg/kg significantly reversed the reduced glutathione (GSH) level, the ratio of GSH/oxidized glutathione, and the reactive oxygen species level in rat lungs from the MA group. These findings suggested that fluoxetine, a SERT inhibitor, has a protective effect against MA‑induced lung inflammation by suppressing oxidative stress through the SERT/p38 MAPK/Nrf2 pathway in rats.

View Figures

View References

1	Rawson RA: Current research on the epidemiology, medical and psychiatric effects, and treatment of methamphetamine use. J Food Drug Anal. 21:S77–S81. 2013. View Article : Google Scholar : PubMed/NCBI
2	Albertson TE, Derlet RW and Van Hoozen BE: Methamphetamine and the expanding complications of amphetamines. West J Med. 170:214–219. 1999.PubMed/NCBI
3	Volkow ND, Fowler JS, Wang GJ, Shumay E, Telang F, Thanos PK and Alexoff D: Distribution and pharmacokinetics of methamphetamine in the human body: Clinical implications. PLoS One. 5:e152692010. View Article : Google Scholar : PubMed/NCBI
4	Peerzada H, Gandhi JA, Guimaraes AJ, Nosanchuk JD and Martinez LR: Methamphetamine administration modifies leukocyte proliferation and cytokine production in murine tissues. Immunobiology. 218:1063–1068. 2013. View Article : Google Scholar : PubMed/NCBI
5	Ma J, Wan J, Meng J, Banerjee S, Ramakrishnan S and Roy S: Methamphetamine induces autophagy as a pro-survival response against apoptotic endothelial cell death through the Kappa opioid receptor. Cell Death Dis. 5:e10992014. View Article : Google Scholar : PubMed/NCBI
6	Wang Y, Liu M, Wang HM, Bai Y, Zhang XH, Sun YX and Wang HL: Involvement of serotonin mechanism in methamphetamine-induced chronic pulmonary toxicity in rats. Hum Exp Toxicol. 32:736–746. 2013. View Article : Google Scholar : PubMed/NCBI
7	Hollinger MA: Drug-induced lung toxicity. Int J Toxicol. 12:31–47. 1993. View Article : Google Scholar
8	Kushnir-Sukhov NM, Gilfillan AM, Coleman JW, Brown JM, Bruening S, Toth M and Metcalfe DD: 5-hydroxytryptamine induces mast cell adhesion and migration. J Immunol. 177:6422–6432. 2006. View Article : Google Scholar : PubMed/NCBI
9	de Las Casas-Engel M and Corbí AL, . Serotonin modulation of macrophage polarization: Inflammation and beyond. Adv Exp Med Biol. 824:89–115. 2014. View Article : Google Scholar : PubMed/NCBI
10	Mann DA and Oakley F: Serotonin paracrine signaling in tissue fibrosis. Biochim Biophys Acta. 1832:905–910. 2013. View Article : Google Scholar : PubMed/NCBI
11	Tanaka T, Doe JM, Horstmann SA, Ahmad S, Ahmad A, Min SJ, Reynolds PR, Suram S, Gaydos J, Burnham EL and Vandivier RW: Neuroendocrine signaling via the serotonin transporter regulates clearance of apoptotic cells. J Biol Chem. 289:10466–10475. 2014. View Article : Google Scholar : PubMed/NCBI
12	Liu M, Wang Y, Wang HM, Bai Y, Zhang XH, Sun YX and Wang HL: Fluoxetine attenuates chronic methamphetamine-induced pulmonary arterial remodelling: Possible involvement of serotonin transporter and serotonin 1B receptor. Basic Clin Pharmacol Toxicol. 112:77–82. 2013. View Article : Google Scholar : PubMed/NCBI
13	Dempsie Y and MacLean MR: Pulmonary hypertension: Therapeutic targets within the serotonin system. Br J Pharmacol. 155:455–462. 2008. View Article : Google Scholar : PubMed/NCBI
14	Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR, McMurtry IF, Stenmark KR, Thistlethwaite PA, Weissmann N, et al: Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol. 54(1 Suppl): S20–S31. 2009. View Article : Google Scholar : PubMed/NCBI
15	Dizeyi N, Hedlund P, Bjartell A, Tinzl M, Austild-Taskén K and Abrahamsson PA: Serotonin activates MAP kinase and PI3K/Akt signaling pathways in prostate cancer cell lines. Urol Oncol. 29:436–445. 2011. View Article : Google Scholar : PubMed/NCBI
16	Wang Y, Han DD, Wang HM, Liu M, Zhang XH and Wang HL: Downregulation of osteopontin is associated with fluoxetine amelioration of monocrotaline-induced pulmonary inflammation and vascular remodelling. Clin Exp Pharmacol Physiol. 38:365–372. 2011. View Article : Google Scholar : PubMed/NCBI
17	Singh M, Foster CR, Dalal S and Singh K: Osteopontin: Role in extracellular matrix deposition and myocardial remodeling post-MI. J Mol. Cell Cardiol. 48:538–543. 2010. View Article : Google Scholar
18	Sahu BD, Mahesh Kumar J and Sistla R: Baicalein, a bioflavonoid, prevents cisplatin-induced acute kidney injury by up-regulating antioxidant defenses and down-regulating the MAPKs and NF-κB pathways. PLoS One. 10:e01341392015. View Article : Google Scholar : PubMed/NCBI
19	Pandurangan AK, Mohebali N, Norhaizan ME and Looi CY: Gallic acid attenuates dextran sulfate sodium-induced experimental colitis in BALB/c mice. Drug Des Devel Ther. 9:3923–3934. 2015. View Article : Google Scholar : PubMed/NCBI
20	Ryu J, Kwon MJ and Nam TJ: Nrf2 and NF-κB signaling pathways contribute to porphyra-334-mediated inhibition of UVA-induced inflammation in skin fibroblasts. Mar Drugs. 13:4721–4732. 2015. View Article : Google Scholar : PubMed/NCBI
21	Saetta M, Shiner RJ, Angus GE, Kim WD, Wang NS, King M, Ghezzo H and Cosio MG: Destructive index: A measurement of lung parenchymal destruction in smokers. Am Rev Respir Dis. 131:764–769. 1985.PubMed/NCBI
22	Rincon M and Irvin CG: Role of IL-6 in asthma and other inflammatory pulmonary diseases. Int J Biol Sci. 8:1281–1290. 2012. View Article : Google Scholar : PubMed/NCBI
23	Lockett AD, Kimani S, Ddungu G, Wrenger S, Tuder RM, Janciauskiene SM and Petrache I: α1-Antitrypsin modulates lung endothelial cell inflammatory responses to TNF-α. Am J Respir Cell Mol Biol. 49:143–150. 2013. View Article : Google Scholar : PubMed/NCBI
24	Stromps J, Fuchs P, Demir E, Grieb G, Reuber K and Pallua N: Intraalveolar TNF-α in combined burn and inhalation injury compared with intraalveolar interleukin-6. J Burn Care Res. 36:e55–e61. 2015. View Article : Google Scholar : PubMed/NCBI
25	Rothman RB and Baumann MH: Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol Ther. 95:73–88. 2002. View Article : Google Scholar : PubMed/NCBI
26	Cloëz-Tayarani I and Changeux JP: Nicotine and serotonin in immune regulation and inflammatory processes: A perspective. J Leukoc Biol. 81:599–606. 2007. View Article : Google Scholar : PubMed/NCBI
27	Wells SM, Buford MC, Porter VM, Brunell HL, Bunderson-Schelvan M, Nevin AB, Cardozo-Pelaez F and Holian A: Role of the serotonergic system in reduced pulmonary function after exposure to methamphetamine. Am J Respir Cell Mol Biol. 42:537–544. 2010. View Article : Google Scholar : PubMed/NCBI
28	Tavoulari S, Forrest LR and Rudnick G: Fluoxetine (Prozac) binding to serotonin transporter is modulated by chloride and conformational changes. J Neurosci. 29:9635–9643. 2009. View Article : Google Scholar : PubMed/NCBI
29	Rose'Meyer R: A review of the serotonin transporter and prenatal cortisol in the development of autism spectrum disorders. Mol Autism. 4:372013. View Article : Google Scholar : PubMed/NCBI
30	Bai Y, Wang HM, Liu M, Wang Y, Lian GC, Zhang XH, Kang J and Wang HL: 4-Chloro-DL-phenylalanine protects against monocrotaline-induced pulmonary vascular remodeling and lung inflammation. Int J Mol Med. 33:373–382. 2014.PubMed/NCBI
31	Chen HH, Wang TC, Lee YC, Shen PT, Chang JY, Yeh TK, Huang CH, Chang HH, Cheng SY, Lin CY, et al: Novel Nrf2/ARE activator, trans-coniferylaldehyde, induces a HO-1-mediated defense mechanism through a dual p38α/MAPKAPK-2 and PK-N3 signaling pathway. Chem Res Toxicol. 28:1681–1692. 2015. View Article : Google Scholar : PubMed/NCBI
32	Ishikawa T: Genetic polymorphism in the NRF2 gene as a prognosis marker for cancer chemotherapy. Front Genet. 5:3832014. View Article : Google Scholar : PubMed/NCBI
33	Ni S, Wang D, Qiu X, Pang L, Song Z and Guo K: Bone marrow mesenchymal stem cells protect against bleomycin-induced pulmonary fibrosis in rat by activating Nrf2 signaling. Int J Clin Exp Pathol. 8:7752–7761. 2015.PubMed/NCBI
34	Richie JP Jr, Nichenametla S, Neidig W, Calcagnotto A, Haley JS, Schell TD and Muscat JE: Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. Eur J Nutr. 54:251–263. 2015. View Article : Google Scholar : PubMed/NCBI
35	Sinha-Hikim I, Shen R, Lee WN Paul, Crum A, Vaziri ND and Norris KC: Effects of a novel cystine-based glutathione precursor on oxidative stress in vascular smooth muscle cells. Am J Physiol Cell Physiol. 299:C638–C642. 2010. View Article : Google Scholar : PubMed/NCBI
36	Qin T, Yin Y, Yu Q and Yang Q: Bursopentin (BP5) protects dendritic cells from lipopolysaccharide-induced oxidative stress for immunosuppression. PLoS One. 10:e01174772015. View Article : Google Scholar : PubMed/NCBI
37	Wang AL, Niu Q, Shi N, Wang J, Jia XF, Lian HF, Liu Z and Liu CX: Glutamine ameliorates intestinal ischemia-reperfusion Injury in rats by activating the Nrf2/Are signaling pathway. Int J Clin Exp Pathol. 8:7896–7904. 2015.PubMed/NCBI